logo.jpg
Zylö’s ‘Powered By Z-pod’ Technology Featured in Peer-Reviewed Paper Published in Experimental Dermatology
27 sept. 2023 08h30 HE | Zylö Therapeutics
Z-pods significantly improved outcomes in mouse model of cutaneous lupus GREENVILLE, SC, Sept. 27, 2023 (GLOBE NEWSWIRE) -- The Z-pod® topical delivery platform was used in various in vivo...
tiziana-logo.png
Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
06 sept. 2023 07h00 HE | Tiziana Life Sciences Ltd.
The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”FDA has cleared the IND for intranasal...
LOGO.png
How Indian outsourcing industry is moving up the value chain - Article published in TOI
28 déc. 2022 10h00 HE | Integra Global Solutions
Pittsburgh, PA, Dec. 28, 2022 (GLOBE NEWSWIRE) -- We are excited to announce that Ganesh Ranganathan, Chairman, and CEO of Integra Global Solutions’ article has been published in the Voices segment...
Axim-Sapphire_Logo_-04 (1).png
AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with a Third COVID-19 Vaccine Dose
12 juil. 2022 09h00 HE | AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company, announced today their...
Logo.jpg
LiveCare Inc. Published PCAOB Audit For Fiscal Year 2021; Validates Proof of Concept
01 juin 2022 11h18 HE | LiveCare Inc.
Venice, FL USA, June 01, 2022 (GLOBE NEWSWIRE) -- LiveCare Inc. OTC:(LVCE), With the completion of its fiscal year 2021 PCAOB audit, validates its proof of concept as an innovative leader in the...
COLORESCIENCE® REVEALS CLINICAL STUDY RESULTS OF THE FINISHING TOUCH™ SKINCARE PROTOCOL FOLLOWING FACIAL RADIOFREQUENCY MICRONEEDLING PROCEDURES
25 mai 2022 08h45 HE | Colorescience
Carlsbad, CA, May 25, 2022 (GLOBE NEWSWIRE) -- In the midst of Skin Cancer Awareness Month, Colorescience®, a leading dermatologist-recommended specialty skincare and cosmetics company announces...
AIMLogo.jpg
Hemispherx Biopharma Reports New Evidence -- Based Potential of Ampligen(R) Against Ebola Virus Disease (EVD)
30 oct. 2014 08h30 HE | AIM ImmunoTech Inc.
PHILADELPHIA, Oct. 30, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today a new peer reviewed publication entitled, "The Quest for...
AIMLogo.jpg
Hemispherx's Two Drugs, Ampligen(R) and Alferon(R) Ranked Highly in Sensitivity Testing Against MERS/SARS Coronaviruses
04 août 2014 08h30 HE | AIM ImmunoTech Inc.
PHILADELPHIA, Aug. 4, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today a peer-reviewed electronic publication entitled "Sensitivity of SARS/MERS CoV to Interferons and...
AIMLogo.jpg
Hemispherx Biopharma Announces New Publication Enlarges the Understanding of Ampligen(R) Safety Profile Across Diverse Animal Species and Focuses on the Unique TLR-3 Receptor/Ampligen(R) Interaction
08 avr. 2014 08h30 HE | AIM ImmunoTech Inc.
PHILADELPHIA, April 8, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") announced today the peer-reviewed publication titled "Discordant Biological and...